Last reviewed · How we verify
NCT05867095: N16LND
Navigated Abdominal Lymph Node Dissections
NA trial testing Surgical navigation in Image-guide Surgery in 69 participants. Completed in 14 October 2021.
14 October 2021
Quick facts
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 69 |
| Start date | 24 January 2017 |
| Primary completion | 14 October 2021 |
| Estimated completion | 14 October 2021 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Surgical navigation
- Conventional
Conditions studied
- Image-guide Surgery — all drugs for Image-guide Surgery →
- Lymph Node Metastasis — all drugs for Lymph Node Metastasis →
Sponsor
The Netherlands Cancer Institute
Who can join
18 and older, any sex, with Image-guide Surgery or Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Image-guided navigation surgery allows for full utilization of pre-operative imaging during surgery, and has the potential of reducing both irradical resections and morbidity. In this study we will randomize patients which will undergo an abdominal lymph node dissection in order to evaluate the actual technical and clinical benefit of navigation
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Surgical navigation for targeted retroperitoneal lymph-node removal: a randomised, controlled, phase 3 trial.
Groen HC, Wit EMK, Heerink WJ, Kuhlmann KFD, et al · · 2024 · cited 4× · PMID 39737148 · DOI 10.1016/j.eclinm.2024.102754
Verify or expand the search:
- PubMed search for NCT05867095
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Netherlands Cancer Institute trials
Trials by the same sponsor.
- NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05867095 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05867095.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing